VISX and Summit dissolve Pillar Point partnership amid legal battles
This article was originally published in Clinica
The six-year old partnership to share patents in the laser eye surgery industry, which was claimed to have been instrumental in artificially raising prices in the US, is over. VISX and Summit Technology agreed last week to dissolve Pillar Point Partners, their vehicle formed in 1992 to license patents jointly and collect a $250 fee per eye for each procedure carried out in the US.
You may also be interested in...
India’s Sun Pharma has been denied leave to appeal against a US court decision rejecting the company’s bid for dismissal of a multi-district antitrust lawsuit.
Former Sandoz executive Hector Armando Kellum has admitted involvement in a US generic price-fixing conspiracy, the US Department of Justice has announced.
The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.